CN1461304A - 作为双组织胺h1和h3促效剂或拮抗剂的取代的咪唑类化合物 - Google Patents

作为双组织胺h1和h3促效剂或拮抗剂的取代的咪唑类化合物 Download PDF

Info

Publication number
CN1461304A
CN1461304A CN01815990A CN01815990A CN1461304A CN 1461304 A CN1461304 A CN 1461304A CN 01815990 A CN01815990 A CN 01815990A CN 01815990 A CN01815990 A CN 01815990A CN 1461304 A CN1461304 A CN 1461304A
Authority
CN
China
Prior art keywords
compound
low
mmol
preparation
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01815990A
Other languages
English (en)
Chinese (zh)
Inventor
辛南阳
R·G·艾斯拉南
D·M·所罗门
S·B·罗森布拉姆
M·W·穆塔席
W·C·唐
K·D·麦克柯米克
J·J·皮温斯基
R·渥林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN1461304A publication Critical patent/CN1461304A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN01815990A 2000-09-20 2001-09-18 作为双组织胺h1和h3促效剂或拮抗剂的取代的咪唑类化合物 Pending CN1461304A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23403900P 2000-09-20 2000-09-20
US60/234,039 2000-09-20

Publications (1)

Publication Number Publication Date
CN1461304A true CN1461304A (zh) 2003-12-10

Family

ID=22879625

Family Applications (1)

Application Number Title Priority Date Filing Date
CN01815990A Pending CN1461304A (zh) 2000-09-20 2001-09-18 作为双组织胺h1和h3促效剂或拮抗剂的取代的咪唑类化合物

Country Status (14)

Country Link
US (1) US6762186B2 (enExample)
EP (1) EP1318996B1 (enExample)
JP (1) JP2004514709A (enExample)
CN (1) CN1461304A (enExample)
AR (1) AR032894A1 (enExample)
AT (1) ATE283853T1 (enExample)
AU (1) AU2002241459A1 (enExample)
CA (1) CA2422729A1 (enExample)
DE (1) DE60107586T2 (enExample)
ES (1) ES2233708T3 (enExample)
HK (1) HK1052182B (enExample)
MX (1) MXPA03002446A (enExample)
TW (1) TWI228127B (enExample)
WO (1) WO2002044141A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110878069A (zh) * 2019-12-09 2020-03-13 南京杰运医药科技有限公司 一种4-吗琳基-2-乙基哌嗪的制备方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1585731A2 (en) * 2002-09-18 2005-10-19 Eli Lilly And Company Histamine h3 receptor antagonists, preparaton and therapeutic uses
US8063650B2 (en) 2002-11-27 2011-11-22 Rambus Inc. Testing fuse configurations in semiconductor devices
US20050090527A1 (en) * 2003-01-28 2005-04-28 Schering Corporation Combination of H1, H3 and H4 receptor antagonists for treatment of allergic and non-allergic pulmonary inflammation, congestion and allergic rhinitis
KR20060066070A (ko) 2003-07-28 2006-06-15 스미스클라인 비참 코포레이션 에스트로겐 수용체의 조절제로서의 시클로알킬리덴 화합물
TWI290140B (en) * 2003-08-25 2007-11-21 Schering Corp 2-Substituted benzimidazole derivatives as selective melanin concentrating hormone receptor antagonists for thr treatment of obesity and related disorders
JP2009504637A (ja) * 2005-08-08 2009-02-05 アストラゼネカ・アクチエボラーグ 治療薬
CA2653497A1 (en) * 2006-05-26 2007-12-06 Neuromed Pharmaceuticals Ltd. Heterocyclic compounds as calcium channel blockers
DE602007012308D1 (de) 2006-12-22 2011-03-10 Avexa Ltd Bicyclische pyrimidinone und deren verwendung
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2586562B1 (fr) * 1985-09-02 1989-03-10 Inst Nat Sante Rech Med Composition pharmaceutique contenant de l'a-methylhistamine
US4829065A (en) * 1987-04-24 1989-05-09 Syntex Pharmaceuticals, Ltd. Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives
GB8916947D0 (en) 1989-07-25 1989-09-13 Smith Kline French Lab Medicaments
EP0437645B1 (de) * 1990-01-15 1995-03-29 HEUMANN PHARMA GMBH & CO Imidazolylpropylguanidinderivat, Verfahren zu seiner Herstellung und diese Verbindung enthaltende Arzneimittel
DK0448765T3 (da) 1990-03-30 1994-09-19 Heumann Pharma Gmbh & Co Anvendelse af guanidinderivater til fremstilling af et lægemiddel med NPY-antagonistisk virkning
FR2665160A1 (fr) * 1990-07-26 1992-01-31 Esteve Labor Dr Nouveaux derives de 1-diphenylmethylpiperazine, leur preparation et leur application en tant que medicaments.
GB9115740D0 (en) 1991-07-20 1991-09-04 Smithkline Beecham Plc Medicaments
CA2125964C (en) 1991-12-18 2001-06-19 Neng-Yang Shih Imidazolyl-alkyl-piperazine and -diazepine derivatives as histamine h3 agonists/antagonists
US5352707A (en) * 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
HU213104B (en) * 1992-06-17 1997-02-28 Richter Gedeon Vegyeszet Process for producing 4-methyl-2-imidazolinone derivatives and pharmaceutical compositions containing them
HUT74386A (en) 1993-11-15 1996-12-30 Schering Corp Phenyl-alkyl imidazoles as h3-receptor antagonists and pharmaceutical compositions containing them
FR2732017B1 (fr) 1995-03-21 2000-09-22 Inst Nat Sante Rech Med Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
DK1019050T3 (da) 1997-06-24 2002-07-08 Novo Nordisk As Anvendelse af somatostatinagonister og -antagonister til behandling af sygdomme i forbindelse med øjet
US5869479A (en) * 1997-08-14 1999-02-09 Schering Corporation Treatment of upper airway allergic responses
US6133291A (en) * 1998-10-16 2000-10-17 Schering Corporation N-(imidazolylalkyl)substituted cyclic amines as histamine-H3 agonists or antagonists

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110878069A (zh) * 2019-12-09 2020-03-13 南京杰运医药科技有限公司 一种4-吗琳基-2-乙基哌嗪的制备方法

Also Published As

Publication number Publication date
US6762186B2 (en) 2004-07-13
US20020082278A1 (en) 2002-06-27
CA2422729A1 (en) 2002-06-06
EP1318996B1 (en) 2004-12-01
WO2002044141A3 (en) 2002-11-07
JP2004514709A (ja) 2004-05-20
HK1052182A1 (en) 2003-09-05
DE60107586D1 (de) 2005-01-05
EP1318996A2 (en) 2003-06-18
DE60107586T2 (de) 2005-10-06
ATE283853T1 (de) 2004-12-15
TWI228127B (en) 2005-02-21
AR032894A1 (es) 2003-12-03
MXPA03002446A (es) 2003-06-19
AU2002241459A1 (en) 2002-06-11
HK1052182B (en) 2005-04-01
WO2002044141A2 (en) 2002-06-06
ES2233708T3 (es) 2005-06-16

Similar Documents

Publication Publication Date Title
CN1129581C (zh) 氰基苯基衍生物
CN1589269A (zh) 杂1,2－二氢化茚:一类新型有效的大麻配体
CN1146559C (zh) 毒蕈碱性拮抗剂
CN1649845A (zh) 蝇蕈碱拮抗剂
CN1434806A (zh) 取代的咪唑神经肽yy5受体拮抗剂
CN1198817C (zh) 作为组胺－h3激动剂或拮抗剂的n－(咪唑基烷基)取代的环胺
JP2010513520A (ja) Ｃｘｃｒ３アンタゴニスト活性を有する複素環式化合物
CN1387526A (zh) 作为cgrp拮抗剂的新环丙烷、包含该化合物的药物及其生产方法
CN1461304A (zh) 作为双组织胺h1和h3促效剂或拮抗剂的取代的咪唑类化合物
CN1933832A (zh) 离子通道调节剂
EP2480232B1 (en) Disubstituted ]4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones
JP2001522836A (ja) Ｈ３レセプターアンタゴニストとしてのフェニル−アルキル−イミダゾール
CN1461303A (zh) 作为双重组胺h1和h3促效剂或拮抗剂的取代咪唑
CN1558907A (zh) 作为双重组胺h1和h3促效剂或拮抗剂的取代咪唑
CN1461299A (zh) 作为双重组胺h1和h3促效剂或拮抗剂的取代咪唑
CN1942447A (zh) 离子通道调节剂
CN1158276C (zh) 具有抑制tnf活性的苯基-和吡啶基-四氢吡啶
CN1043764C (zh) 作为5－ht1a拮抗剂的双环甲酰胺
CN1134433C (zh) 法呢基蛋白转移酶的新的氨基氧酰胺三环抑制剂
HK1167605B (en) Disubstituted [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication